Topical 5% ET-02 Increased Hair Growth in 28 Days Compares Favorably with Reported Results for Topical and Oral Minoxidil Phase 2 Clinical Trial Expected to Begin in 2027 September 16, 2026 – Woburn, MA – Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, today announced that the company will make a scientific presentation about its product candidate ET-02 for androgenetic alopecia at the Third BCN

WOBURN, Mass., July 9, 2025 /PRNewswire/ Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic...

Eirion’s CEO Interviewed in the Podcast Series Visionary Voices about ET-02 for Hair Loss May 7, 2025 – Woburn, MA – Eirion Therapeutics...